16% — Will the CDC end its recommendation for the Rotavirus vaccine
Leader: COVID-19 at 16% · Kalshi 16% · 5 contracts · $509 volume · medium confidence
Updated 2026-05-09 07:21:48 UTC

Tracks the leading outcome in a winner-take-all prediction market set with 5 outcomes.

Why this matters:
This probability reflects market expectations that the CDC will discontinue its recommendation for rotavirus vaccination at some point in the future. Currently priced at 13%, the market assigns low odds to this outcome occurring. The rotavirus vaccine remains a cornerstone of the childhood immunization schedule in the United States, with strong clinical evidence supporting its safety and effectiveness in preventing severe gastroenteritis. Market participants likely weigh the vaccine's established track record against potential future developments: emerging epidemiological data suggesting reduced disease burden, safety signals from adverse event monitoring systems, policy shifts prioritizing resource allocation, or changes in disease prevalence patterns. The outcome depends on CDC advisory committee deliberations and formal recommendation updates, which occur periodically but without fixed schedules. Resolution requires an official CDC statement ending the rotavirus vaccine recommendation for routine childhood immunization.

Key factors:
- Current rotavirus vaccine coverage remains high (>90% among U.S. children), with no recent safety alerts or efficacy concerns in CDC surveillance systems
- CDC's routine immunization recommendations rarely get rescinded absent compelling evidence of diminished disease burden or serious adverse events
- Any recommendation change would require peer-reviewed epidemiological data demonstrating rotavirus no longer poses a significant public health threat in the U.S.
- International vaccine policy shifts or WHO guidance changes could indirectly influence CDC decision-making, though the U.S. tends to maintain independent assessment
- The timeline for any potential review is undefined; CDC periodically reassesses vaccines through ACIP but has no announced schedule for rotavirus re-evaluation

Contracts:
- Will the CDC end its recommendation for the COVID-19 vaccine?: COVID-19 — 16¢ Kalshi $509 (weight 100%)
- Will the CDC end its recommendation for the Influenza vaccine?: Influenza — 10¢ Kalshi $0 (weight 0%)
- Will the CDC end its recommendation for the Hepatitis B vaccine?: Hepatitis B — 9¢ Kalshi $0 (weight 0%)
- Will the CDC end its recommendation for the Polio vaccine?: Polio — 4¢ Kalshi $0 (weight 0%)
- Will the CDC end its recommendation for the Rotavirus vaccine?: Rotavirus — 3¢ Kalshi $0 (weight 0%)

Cite as: "16% per prediction markets (SimpleFunctions, May 2026)"
Canonical: https://simplefunctions.dev/answer/vaccinerec
Full data: https://simplefunctions.dev/api/public/query?q=Will%20the%20CDC%20end%20its%20recommendation%20for%20the%20Rotavirus%20vaccine
Provider: SimpleFunctions — https://simplefunctions.dev